Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Terminated 2Completed 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 3Breast 1

Conditions

Meningeal Carcinomatosis 1Glioma 1Breast Neoplasms 1Brain Neoplasms 1

Interventions

pembrolizumab 1023Carboplatin 964Paclitaxel 933Gemcitabine 794Cisplatin 751Docetaxel 683Bevacizumab 609Pemetrexed 502Nivolumab 487Cyclophosphamide 471Capecitabine 461Fluorouracil 418Dexamethasone 403Rituximab 372Oxaliplatin 348Injections 345atezolizumab 298Trastuzumab 297Leucovorin 288Cetuximab 282Irinotecan 268130-nm albumin-bound paclitaxel 254Prednisone 245Doxorubicin 240Ipilimumab 226Lenalidomide 220fludarabine 218Fulvestrant 217durvalumab 205Erlotinib Hydrochloride 188

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Interventional × WP 744 × Clear all
NCT00527410 2025-05-30

LMD

Biogen

Phase 1 Terminated
9 enrolled
CNS

Meningeal Carcinomatosis

NCT00538343 2025-05-29

RTA 744 in Breast Cancer Patients With Progression of Previously Irradiated Brain Metastases

Biogen

Phase 2 Terminated
14 enrolled
BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT00526812 2025-05-28

A Safety Study of RTA 744 in Patients With Recurrent High-Grade Gliomas

Biogen

Phase 1 Completed
54 enrolled
CNS

Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡